

In the originally published article: Gori N, Sernicola A, Ippoliti E, Coppola R, Maurelli M, Ortoncelli M, et al. *Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations* Acta Derm Venereol 2025; 105: adv43523. DOI: 10.2340/actadv.v105.43523, the authors have identified errors in the published article. The following text and Figure 1 should be corrected. These corrections do not alter the overall interpretation of the study findings. The authors apologize for the errors.

Clinical response on page 3

Original sentence: "The proportion of patients achieving EASI 75 and 90 was 56.7% and 41.7% at week 16, increasing to 84% and 82% at week 52, respectively (Table III)."

Corrected sentence: "The proportion of patients achieving EASI 75 and 90 was 48.6% (34/70) and 35.7% (25/70) at week 16, increasing to 84% (42/50) and 82% (41/50) at week 52, respectively (Table III)."

Chronic viral infections on page 3

Original sentence: "In total, 9 patients (7.8%) were affected by chronic viral infection, including 3 patients with HIV, 3 patients with HCV, 3 with HBV, and 1 patient with concomitant HIV and HCV infection."

Corrected sentence: "In total, 9 patients (12.9%) had a chronic viral infection: 3 had HIV infection alone, 3 had HCV infection alone, 2 had HBV infection, and 1 had concomitant HIV and HCV infection."

In the Discussion, the reduction in DLQI from baseline to week 16 is reported as 94.3%. Based on the values in Table III (15.7 and 3.9, respectively), the correct reduction is 75.2%.

Discussion on page 6

Original sentence: "In this regard, our study enrolled 9 patients with chronic viral diseases, including 4 cases of HIV, 4 cases of HCV, and 2 cases of HBV."

Corrected sentence: "In this regard, our study enrolled 9 patients with chronic viral infections: 4 patients had HIV (including 1 with concomitant HCV infection), 4 had HCV (including the same coinfecting patient), and 2 had HBV."

Figure 1 on page 4

The published EASI plot starts at week 16 and omits baseline (week 0).




Fig. 1. Mean improvement in Eczema Area and Severity Index (EASI) score observed up to week 156.